Natural History Study of Patients With Centronuclear Myopathies

Withdrawn

• Conditions: Centronuclear Myopathy

• Registration Number: NCT04977648
• Lead Sponsor: Dynacure

Brief Summary

This is a prospective, longitudinal study of the natural disease course intended to recruit approximately 60 patients with centronuclear myopathies (CNM) in Europe and the United States. The duration of the study, including the enrollment period, will be approximately 4 years. Data from the study will be used to characterize the natural disease course of CNM, to identify prognostic variables of the disease and to determine the best outcome measure(s) for the evaluation of future therapeutic approaches.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-05-21
• Study First Submitted QC: 2021-07-15
• Study First Posted: 2021-07-27
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-07
• Last Update Posted: 2022-07-11
• Study Start: 2022-09
• Primary Completion: 2026-03
• Study Completion: 2026-03

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• 1. Clinically symptomatic male or female subjects of all ages (newborns included) with a CNM resulting from a documented mutation in the MTM1 or DNM2 gene.
• 2. A written, signed and dated informed consent must be provided to participate in the study. For subjects <18 years, consent of parent(s)/legal guardian(s) is required; informed assent can be obtained from the child according to local regulations.
• 3. Willing and able to comply with all protocol requirements and procedures.

Exclusion Criteria

• 1. Participation in any other interventional study. Participation in a previous study should be completed at least 4 weeks before the first study visit.
• 2. Currently undergoing or has undergone previous gene therapy or other therapy for CNM.
• 3. Current or past abuse of alcohol or recreational/narcotic drugs (with the exception of caffeine and nicotine), which in the investigator's opinion would compromise the subject's safety and/or compliance with the study procedures.
• 4. Current or relevant history of physical or psychiatric illness, that would make the subject unlikely to comply with the study procedures. (Note: Subjects in a wheelchair are not to be excluded).
• 5. Subject is mentally incapacitated, or parent(s)/legally-authorized representative are legally incapacitated or have limited legal capacity, or have lack of mental capacity to fully understand the protocol requirements and complete all study required procedures.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change from baseline in the Peak Inspiratory Pressure (PIP).	Baseline, Up to 36 months	The PIP assessment will be based on subject age and ventilation status. Results will be expressed in cmH2O.
Change from baseline in the Motor Function Measure (MFM32) for neuromuscular diseases.	Baseline, Up to 36 months	The MFM32 assessment will be based on subject age. Scoring from 0 (cannot initiate the task) to 3 (performs the task fully).
Change from baseline in the in Peak Expiratory Pressure (PEP).	Baseline, Up to 36 months	The PEP assessment will be based on subject age and ventilation status. Results will be expressed in cmH2O.

Secondary Outcome Measures

Name	Time	Method
Change from baseline in the Meaningful Use of Speech Scale (MUSS).	Baseline, Up to 36 months	The MUSS will be scored by trained site personnel based on the caregiver's or subject's reporting. Scoring from 0 (never) to 4 (always).
Change from baseline in the Pediatric Quality of Life inventory (PedsQL™).	Baseline, Up to 36 months	The PedsQL™ questionnaire will be completed by the caregivers or by subjects based on subject age.
Change from baseline in the Assessment of Caregiver Experience with Neuromuscular Disease (ACEND).	Baseline, Up to 36 months	The ACEND questionnaire will be completed by the caregiver for subjects in the study. Scoring from 1 (needs full time assistance) to 6 (needs no assistance).
Change from baseline in the (Pediatric) Eating Assessment Tool-10 ([Pedi]-EAT-10).	Baseline, Up to 36 months	The (Pedi)-EAT-10 assessment will be completed by the caregiver based on subject age. Scoring from 0 (no problem) to 4 (severe problem).